Literature DB >> 23627311

Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.

Rose M Santangelo Freel1, Kevin K Ogden, Katie L Strong, Alpa Khatri, Kathryn M Chepiga, Henrik S Jensen, Stephen F Traynelis, Dennis C Liotta.   

Abstract

We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler-Napieralski conditions were employed in the key step for the conversion of acyclic amides to the corresponding tetrahydroisoquinoline-containing analogs. Compounds were evaluated using both two-electrode voltage clamp recordings from Xenopus laevis oocytes and imaging of mammalian BHK cells loaded with Ca(2+)-sensitive dyes. The most potent analogues had EC50 values of 300 nM and showed over 2-fold potentiation of the response to maximally effective concentrations of glutamate and glycine but had no effect on responses from NMDA receptors containing the GluN2A or GluN2B subunits AMPA, kainate, and GABA or glycine receptors or a variety of other potential targets. These compounds represent a potent class of small molecule subunit-selective potentiators of NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627311      PMCID: PMC4850841          DOI: 10.1021/jm400177t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  66 in total

1.  In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist.

Authors:  Sayoko Suetake-Koga; Toshiharu Shimazaki; Kazuaki Takamori; Shigeyuki Chaki; Kosuke Kanuma; Yoshinori Sekiguchi; Tsutomu Suzuki; Toyohiko Kikuchi; Yoshimitsu Matsui; Toshio Honda
Journal:  Pharmacol Biochem Behav       Date:  2006-06-09       Impact factor: 3.533

2.  Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors.

Authors:  T Masuko; T Kuno; K Kashiwagi; T Kusama; K Williams; K Igarashi
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

3.  Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors.

Authors:  D J Wyllie; P Béhé; D Colquhoun
Journal:  J Physiol       Date:  1998-07-01       Impact factor: 5.182

4.  NMDA receptor and schizophrenia: a brief history.

Authors:  Joseph T Coyle
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

5.  Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators.

Authors:  Timothy M Acker; Hongjie Yuan; Kasper B Hansen; Katie M Vance; Kevin K Ogden; Henrik S Jensen; Pieter B Burger; Praseeda Mullasseril; James P Snyder; Dennis C Liotta; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2011-08-01       Impact factor: 4.436

6.  Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.

Authors:  Blaise Mathias Costa; Mark W Irvine; Guangyu Fang; Richard J Eaves; Maria Belen Mayo-Martin; Bodo Laube; David E Jane; Daniel T Monaghan
Journal:  Neuropharmacology       Date:  2011-12-06       Impact factor: 5.250

7.  Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain.

Authors:  R P Simon; J H Swan; T Griffiths; B S Meldrum
Journal:  Science       Date:  1984-11-16       Impact factor: 47.728

8.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

9.  The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat.

Authors:  C K Park; D G Nehls; D I Graham; G M Teasdale; J McCulloch
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

Review 10.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  19 in total

1.  PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits.

Authors:  Feng Yi; Nirvan Rouzbeh; Kasper B Hansen; Yuelian Xu; Christopher M Fanger; Earl Gordon; Kathy Paschetto; Frank S Menniti; Robert A Volkmann
Journal:  Neuropharmacology       Date:  2020-01-25       Impact factor: 5.250

2.  The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor.

Authors:  Thomas M Kaiser; Steven A Kell; Hirofumi Kusumoto; Gil Shaulsky; Subhrajit Bhattacharya; Matthew P Epplin; Katie L Strong; Eric J Miller; Bryan D Cox; David S Menaldino; Dennis C Liotta; Stephen F Traynelis; Pieter B Burger
Journal:  Mol Pharmacol       Date:  2017-12-14       Impact factor: 4.436

3.  Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice.

Authors:  Kevin K Ogden; Alpa Khatri; Stephen F Traynelis; Scott A Heldt
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

4.  Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.

Authors:  Timothy M Acker; Alpa Khatri; Katie M Vance; Cathryn Slabber; John Bacsa; James P Snyder; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2013-08-02       Impact factor: 7.446

5.  Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors.

Authors:  Patrick M Callahan; Alvin V Terry; Frederick R Nelson; Robert A Volkmann; A B Vinod; Mohd Zainuddin; Frank S Menniti
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

6.  The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors.

Authors:  Katie L Strong; Matthew P Epplin; John Bacsa; Christopher J Butch; Pieter B Burger; David S Menaldino; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2017-06-26       Impact factor: 7.446

Review 7.  Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors.

Authors:  Hualong Fu; Zhen Chen; Lee Josephson; Zijing Li; Steven H Liang
Journal:  J Med Chem       Date:  2018-08-27       Impact factor: 7.446

Review 8.  NMDA receptor modulators: an updated patent review (2013-2014).

Authors:  Katie L Strong; Yao Jing; Anthony R Prosser; Stephen F Traynelis; Dennis C Liotta
Journal:  Expert Opin Ther Pat       Date:  2014-10-29       Impact factor: 6.674

9.  GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.

Authors:  Riley E Perszyk; John O DiRaddo; Katie L Strong; Chian-Ming Low; Kevin K Ogden; Alpa Khatri; Geoffrey A Vargish; Kenneth A Pelkey; Ludovic Tricoire; Dennis C Liotta; Yoland Smith; Chris J McBain; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2016-09-13       Impact factor: 4.436

10.  Novel PAMs Targeting NMDAR GluN2A Subunit.

Authors:  Zixiu Xiang; P Jeffrey Conn
Journal:  Neuron       Date:  2016-03-02       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.